Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $223000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 13.9% year-over-year to $223000.0; the TTM value through Sep 2025 reached $980000.0, down 0.91%, while the annual FY2024 figure was $1.0 million, 25.06% up from the prior year.
  • Depreciation & Amortization (CF) reached $223000.0 in Q3 2025 per RANI's latest filing, down from $240000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $266000.0 in Q4 2024 and bottomed at $111000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $189947.4, with a median of $189000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 18.38% in 2022, then surged 69.37% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $113000.0 in 2021, then skyrocketed by 53.98% to $174000.0 in 2022, then surged by 30.46% to $227000.0 in 2023, then rose by 17.18% to $266000.0 in 2024, then dropped by 16.17% to $223000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $223000.0 in Q3 2025, $240000.0 in Q2 2025, and $251000.0 in Q1 2025.